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SUMMARY 
 AMP-activated protein kinase (AMPK) is a key regulator of cellular and whole body 
energy balance. AMPK phosphorylates and regulates many proteins concerned with 
nutrient metabolism, largely acting to suppress anabolic ATP-consuming pathways whilst 
stimulating catabolic ATP-generating pathways. This has led to considerable interest in 
AMPK as a therapeutic target for the metabolic dysfunction observed in obesity and insulin 
resistance. The role of AMPK in skeletal muscle and the liver has been extensively 
studied, such that AMPK has been demonstrated to inhibit synthesis of fatty acids, 
cholesterol and isoprenoids, hepatic gluconeogenesis and translation whilst increasing 
fatty acid oxidation, muscle glucose transport, mitochondrial biogenesis and caloric intake. 
The role of AMPK in the other principal metabolic and insulin-sensitive tissue, adipose, 
remains poorly characterised in comparison, yet increasing evidence supports an 
important role for AMPK in adipose tissue function. Obesity is characterised by 
hypertrophy of adipocytes and the development of a chronic sub-clinical proinflammatory 
environment in adipose tissue, leading to increased infiltration of immune cells. This 
combination of dysfunctional hypertrophic adipocytes and a proinflammatory environment 
contributes to insulin resistance and the development of type 2 diabetes.  Exciting recent 
studies indicate that AMPK may not only influence metabolism in adipocytes but also act 
to suppress this proinflammatory environment, such that targeting AMPK in adipose tissue 
may be desirable to normalise adipose dysfunction and inflammation. In this review we 
discuss the role of AMPK in adipose tissue, focussing on the regulation of carbohydrate 
and lipid metabolism, adipogenesis and proinflammatory pathways in physiological and 
pathophysiological conditions.  
 
INTRODUCTION  
 AMP-activated protein kinase (AMPK) is the downstream component of a protein 
kinase cascade that has a central role in the regulation of energy balance at both the 
cellular and whole body level. As a consequence, AMPK activation is proposed to be a 
therapeutic target for the treatment of obesity and type 2 diabetes [1-3]. In addition to the 
metabolic actions of AMPK, increasing evidence suggests that AMPK has anti-
inflammatory actions, independent of its effects on carbohydrate and lipid metabolism [4]. 
Although the role of AMPK in liver and muscle is relatively well-characterised and have 
been reviewed extensively elsewhere [1-3], the role of AMPK in the other principal 
metabolic tissue, adipose, remains less well defined. The relative lack of data concerning 
the role of AMPK in adipose tissue may reflect the heterogeneity of adipose tissue and the 
marked difficulty in using standard molecular biology techniques to specifically up- and 
downregulate AMPK in terminally-differentiated adipocytes when compared to skeletal 
muscle and the liver. Dysfunctional metabolism and a chronic sub-clinical proinflammatory 
environment are observed in the adipose tissue of obese individuals, which contribute to 
the development of systemic insulin resistance and type 2 diabetes [5]. Given the 
metabolic and anti-inflammatory actions of AMPK activation, understanding the role(s) of 
AMPK in adipose tissue is, therefore, of significant importance. The focus of the current 
review is to examine the evidence concerning the actions of AMPK in adipose tissue and 
how these actions may impact on the whole body in the physiological and 
pathophysiological setting. 
 
ADIPOSE TISSUE PHYSIOLOGY 
Adipose tissue composition and function 
At the whole body level, adipose tissue is divided into subcutaneous (SCAT) and 
visceral (VAT) depots. Adipose tissue contains several cell types, including adipocytes, 
immune cells, fibroblasts and preadipocytes, which can differentiate into mature 
adipocytes. Furthermore, adipose tissue contains cells from the vascular and nervous 
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systems [6].  The heterogeneity of adipose tissue is complicated further by the 
classification of adipose tissue as white adipose tissue (WAT) or brown adipose tissue 
(BAT). Adipocytes within WAT serve to store excess dietary calories as triacylglyceride 
(TAG), whereas adipocytes within BAT allow energy dissipation by thermogenesis. In 
addition to its key role in lipid metabolism, WAT also has an endocrine action, secreting a 
large number of proteins, collectively termed adipocytokines, which influence systemic and 
local metabolism and inflammatory pathways. WAT represents the major proportion of 
adipose tissue in humans, although there is increasing evidence that BAT is present in 
significant quantities and co-exists with WAT within the same depot [6,7]. 
White adipocytes contain a single lipid droplet of TAG that is formed from the 
esterification of fatty acids (FAs) and glycerol-3-phosphate. FAs are obtained from 
circulating lipoproteins by lipoprotein lipase (LPL)-mediated lipolysis and transported into 
the adipocyte or synthesised de novo by lipogenesis from non-lipid substrates such as 
glucose [8]. In the fasted state, or during prolonged physical activity, TAG in the lipid 
droplet is hydrolysed to fatty acids and glycerol, for use by other tissues for ATP 
generation or hepatic gluconeogenesis respectively. Insulin is the principal stimulus of 
TAG formation in white adipocytes, stimulating glucose transporter-4 (GLUT4)-mediated 
glucose transport and the activity of acetyl CoA carboxylase (ACC), the rate-limiting step 
of fatty acid synthesis from acetyl CoA [9]. In contrast, adrenergic stimulation of adipose 
tissue stimulates the formation of the second messenger cAMP, with subsequent 
activation of cAMP-dependent protein kinase (PKA) [8]. PKA phosphorylates and activates 
hormone-sensitive lipase (HSL), stimulating lipolysis. Insulin, via PKB (protein kinase B, 
also known as Akt)-mediated phosphorylation and activation of phosphodiesterase 3B 
(PDE3B), stimulates breakdown of cAMP, thereby suppressing lipolysis [8]. 
 Brown adipocytes contain multilocular lipid droplets and high numbers of 
mitochondria. The mitochondria in brown adipocytes characteristically express uncoupling 
protein 1 (UCP1), which uncouples ATP synthesis from substrate oxidation, allowing 
thermogenesis, yet the exact role of BAT in human energy balance remains uncertain 
[6,7].   
 
Adipose tissue and obesity 
 The rising incidence of type 2 diabetes is closely associated with the increased 
prevalence of obesity, particularly expansion of VAT rather than SCAT depots [10]. 
Chronic overfeeding leads to hypertrophy of adipocytes and the development of a chronic 
sub-clinical proinflammatory environment [5]. As a consequence, infiltration of adipose 
tissue with macrophages and other leukocytes occurs, which further exacerbates the 
proinflammatory environment in parallel with increasing insulin resistance of adipocytes 
[5]. The capacity of the dysfunctional adipocytes to store triglycerides becomes impaired, 
leading to ectopic storage of lipid in tissues including the liver and skeletal muscle [5]. 
Increased circulating adipose-derived proinflammatory cytokines, FAs and metabolites of 
this ectopic lipid subsequently impair insulin sensitivity in target tissues [5]. This may 
include cardiovascular tissues as a thin layer of adventitia-associated perivascular adipose 
tissue (PVAT) found in small arteries and arterioles also becomes dysfunctional in obesity 
and type 2 diabetes [11]. Targeting WAT to reduce inflammation has therefore received 
interest as a potential therapeutic target to limit the development of insulin resistance and 
type 2 diabetes. Furthermore, It has been hypothesised that targeting BAT to increase 
energy expenditure might be useful clinically for anti-obesity therapies [7]. 
 
AMPK 
Structure & Regulation  
 Since its initial characterisation as a protein kinase activity activated by AMP [12], 
significant advances have been made in understanding the enzymology of AMPK and 
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these have been reviewed recently elsewhere [2]. Briefly, AMPK is a heterotrimeric 
complex of catalytic  and regulatory and  subunits. Several subunit isoforms of each 
subunit (1, 2, 1, 2, 1, 2 and 3) have been identified in mammals, such that 12 
theoretically possible complexes may be formed.  The isoforms exhibit differential tissue 
expression and may influence subcellular localisation of the resultant AMPK complex 
[13,14]. AMPK is subject to regulation by allosteric mechanisms, and post-translational 
modifications including phosphorylation, myristoylation and acetylation [1,2]. In addition, 
AMPK subunits contain a carbohydrate-binding domain that can interact with 
oligosaccharide components of glycogen, such that glycogen binding may inhibit AMPK 
activity [16]. 
 AMPK subunits contain four cystathionine--synthase (CBS) domains in two 
tandem repeats, with each tandem repeat referred to as a Bateman domain [1]. Adenine 
nucleotides bind to the Bateman domains, with three of the four potential binding sites 
occupied by nucleotides in the crystal structure of the regulatory core of AMPK [17]. Of 
these three sites, one binds AMP tightly, whereas the two remaining sites bind AMP, ADP 
or ATP in a competitive manner, thereby regulating AMPK activity. Binding of AMP or ADP 
promotes phosphorylation of Thr172 on the catalytic  subunit, required for full activation 
of AMPK (Figure 1), whereas binding of ATP competitively antagonises allosteric 
activation and stimulation of Thr172 phosphorylation by AMP or ADP [1,2].  The different  
subunit isoforms exhibit different adenine nucleotide sensitivity, which may contribute to 
tissue-specific AMPK regulation [1,2]. As a consequence, increases in the AMP/ATP or 
ADP/ATP ratio allosterically activate AMPK and further promote activity due to increased 
Thr172 phosphorylation. However, the binding affinities for AMP, ADP or ATP at any given 
site are similar, whereas the cellular concentrations of ATP and ADP are considerably 
higher than AMP, such that it has been argued that the ADP/ATP ratio may be more 
relevant physiological stimulus for AMPK [reviewed in 1,2]. Furthermore, it has been 
reasoned that the degree of activation due to allosteric activation by AMP or ADP is 
modest compared to the effect of phosphorylation at Thr172, such that the effect of 
allosteric activation may be small in vivo [1]. Therefore the regulation of AMPK by adenine 
nucleotides warrants further research, particularly to determine the relationship between 
AMPK activity and the cellular/subcellular concentrations of free ATP, ADP and AMP.     
 Two AMPK kinases have been identified that mediate phosphorylation of the AMPK 
 catalytic subunit at Thr172, liver kinase B1 (LKB1) and Ca2+/calmodulin-dependent 
protein kinase kinase  (CaMKK) (Figure 1). Changes in adenine nucleotide 
concentrations do not directly regulate LKB1 or CaMKK, and it has been demonstrated 
that AMP and ADP binding to the AMPK subunit inhibits dephosphorylation of Thr172 in 
the presence of constitutive LKB1 activity (Figure 1) [18]. Increased intracellular Ca2+ 
concentrations are therefore able to activate AMPK independent of changes in adenine 
nucleotide ratios in cells expressing CaMKK (Figure 1) [19,20].   
 In addition to phosphorylation, AMPK subunits are N-terminally myristoylated, and 
AMPK subunits are acetylated on lysine residues by p300 acetyltransferase [1,21]. 
Hydrogen peroxide has also been reported to activate AMPK via oxidative modification of 
 subunit cysteines, yet the physiological relevance of these modifications have yet to be 
fully characterised [1,22].   
 
Activation and physiological role 
 AMPK is activated under conditions in which cellular energy demands are increased 
or when fuel availability is decreased, due to reduced intracellular ATP and/or increased 
AMP levels [1,2]. As a consequence, physiological stimuli that activate AMPK include 
exercise in muscle, ischaemia, glucose deprivation, heat shock and hypoxia [1,2,23]. 
Activated AMPK subsequently phosphorylates key proteins concerned with the regulation 
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of carbohydrate and lipid metabolism, resulting in inhibition of ATP-consuming anabolic 
pathways including fatty acid synthesis, cholesterol and isoprenoid synthesis, hepatic 
gluconeogenesis and mammalian target of rapamycin (mTOR)-mediated protein 
translation. Concurrently, AMPK activation stimulates ATP production by increasing fatty 
acid oxidation, muscle glucose transport, mitochondrial biogenesis and caloric intake 
[1,2,23]. Thus AMPK maintains cellular energy stores and regulates whole body energy 
balance, leading to the hypothesis that stimulation of AMPK in the metabolic tissues is a 
useful target for therapies to treat obesity, insulin resistance and type 2 diabetes [1,2,23]. 
In support of this, the widely-used hypoglycaemic biguanide drug, metformin and the 
thiazolidinedione class of anti-diabetic drugs stimulate AMPK, although it remains 
uncertain to what extent AMPK activation underlies their clinical action [24-27].  Recently, 
salicylate has been demonstrated to stimulate AMPK [28]. Furthermore, salicylate-
stimulated fatty acid oxidation was absent in AMPK1-/- mice, indicating effects of 
salicylate on lipid metabolism in vivo are mediated by AMPK [28].  
 Several agents have been used experimentally to activate AMPK. AICAR (5’-
aminoimidazole-4-carboxamide ribonucleoside) is a nucleoside that has been used widely 
to activate AMPK in intact cells, tissues and animals. After transport of AICAR into cells, it 
is phosphorylated to the nucleotide ZMP, which mimics AMP, thereby activating AMPK 
without altering adenine nucleotide ratios (Figure 1), although a number of AMPK-
independent effects of AICAR have been identified [27,29].  In addition to metformin and 
thiazolidinediones such as rosiglitazone mentioned above, several plant-derived 
compounds including galgeine, berberine and resveratrol activate AMPK in intact cells by 
altering adenine nucleotide ratios (Figure 1) [30]. Furthermore, the lipid-lowering statin 
drugs, and several adipocytokines and hormones including leptin, adiponectin and ghrelin 
have been demonstrated to activate AMPK in certain tissues, yet the mechanism(s) by 
which they activate AMPK remain poorly characterised [31-34].  The thienopyridone 
A769662 is a recently characterised specific activator of AMPK, which stimulates 
complexes containing the 1, but not 2 regulatory subunit, in an AMP-independent 
manner (Figure 1), demonstrating that selective manipulation of AMPK complexes 
containing specific subunit isoforms is possible [35,36]. Intriguingly the mode of action of 
salicylate is related to that of A769662, which similarly only stimulates AMPK complexes 
containing the 1 non-catalytic subunit and does not alter adenine nucleotide 
concentrations (Figure 1) [28]. 
 
Expression and activation in adipose tissue 
 AMPK1 has been reported to be the principal catalytic subunit isoform expressed 
in human SCAT and mouse BAT as assessed by AMPK activity in immunoprecipitates 
using isoform-specific anti-AMPK subunit antibodies [37,38]. Using similar techniques, 
AMPK1 has also been reported to be the dominant isoform in isolated epididymal rat 
adipocytes and cultured 3T3-L1 adipocytes [39,40]. As these assays assess total 
cellular/tissue AMPK activity, important roles for AMPK complexes containing the 2 
subunit in specific subcellular compartments cannot be excluded, particularly as 
downregulation of AMPK2 in cells where it is only a minor isoform can have marked 
effects [41]. As A769662 and salicylate have been reported to stimulate only AMPK 
complexes containing the 1 subunit isoform, the observations that A769662 activated 
AMPK in 3T3-L1 adipocytes and salicylate activated AMPK in mouse WAT indicate that 
adipose tissue and adipocytes express the 1 subunit isoform [28,42], observations that 
are supported by the modest reduction in AMPK Thr172 and ACC phosphorylation 
reported in the adipose tissue of AMPK1-/- mice [43]. As the reduction in AMPK 
phosphorylation was not substantial, this may suggest that WAT expresses significant 
levels of AMPK2, yet no effect on WAT AMPK activity was observed in AMPK2-/- mice 
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[44], indicating that AMPK1 may be the principal  isoform in WAT. There is little 
published information concerning the AMPK subunit isoform expression in the other cell 
types within WAT or BAT, yet AMPK1 is reported to be the principal catalytic isoform 
expressed in human endothelial cells [41] and mouse macrophages [45], which also 
respond to A769662 or express AMPK1 [46,47]. 
 Several physiological stimuli have been reported to activate adipose AMPK 
including fasting in mouse and rat WAT [40,48], cold exposure in mouse WAT [38] and 
exercise in human SCAT and rat epididymal adipose tissue [49,50]. In contrast, androgens 
have been reported to reduce AMPK activity in mouse WAT [51]. Cold exposure has also 
been reported to stimulate AMPK in BAT from rats and mice [38,52]. Endogenous stimuli 
such as -adrenergic stimulators, high density lipoproteins, homocysteine and 
eicosapentaenoic acid have also been reported to stimulate AMPK activity in isolated 
rodent adipocytes or cultured 3T3-L1 adipocytes [40,53-56], whereas ghrelin and 
testosterone have been reported to inhibit AMPK activity [57,58]. The adipocytokine, 
adiponectin, secreted by adipose tissue has also been reported to activate adipocyte 
AMPK [59], illustrating the potential autocrine regulation of adipocyte AMPK activity. 
Similarly, WAT of mice with an adipose-specific overexpression the leptin receptor 
exhibited increased AMPK Thr172 phosphorylation, suggesting leptin may activate 
adipocyte AMPK in an autocrine manner [60]. Finally, metformin has been demonstrated 
to increase AMPK activity in WAT from mice and volunteers with type 2 diabetes in 
addition to cultured 3T3-L1 adipocytes [61,62]. It is therefore apparent that a number of 
stimuli may regulate adipose AMPK under physiological and pathophysiological conditions. 
 
EFFECT OF AMPK ON ADIPOCYTE CARBOHYDRATE METABOLISM 
Glucose transport 
 In striated muscle and adipocytes, insulin stimulates glucose uptake, mediated by 
translocation of vesicles containing GLUT4 to the plasma membrane (Figure 2). The 
increased influx of glucose provides a substrate for glycogen synthesis in skeletal muscle 
and TAG synthesis in adipocytes. In skeletal muscle, AMPK activation has been 
demonstrated to further increase both basal and insulin-stimulated glucose uptake by 
increasing GLUT4 translocation [63-69]. The effect of AMPK activation on glucose uptake 
in adipocytes, however, is less clear. In 3T3-L1 adipocytes AICAR increased basal [39,70] 
and inhibited insulin-stimulated glucose uptake without affecting early steps in the insulin 
signalling pathway [39,61]. On the other hand, in isolated rat adipocytes AICAR inhibited 
both basal and insulin-stimulated glucose uptake [71,72]. In contrast, AICAR-stimulated 
glucose uptake was not affected by infection of 3T3-L1 adipocytes with adenoviruses 
expressing a dominant negative mutant AMPK, despite complete suppression of AMPK 
activation [70]. Therefore, the involvement of AMPK in the effect of AICAR on basal 
glucose uptake is uncertain. Despite this, most published evidence supports inhibition of 
insulin-stimulated glucose uptake by AMPK in adipocytes without affecting early steps in 
insulin signalling including insulin-stimulated insulin receptor substrate-1 (IRS-1) tyrosine 
phosphorylation [39,73], phosphatidylinositol 3’kinase (PI3K) recruitment to IRS-1 [39] or 
PKB activity/phosphorylation [39,61,72,73].  
 In contrast, treatment of rat adipocytes with globular adiponectin rapidly activated 
AMPK and increased both basal and insulin-stimulated glucose uptake in a manner 
sensitive to two different inhibitors of AMPK, araA and compound C, suggesting 
involvement of AMPK in the stimulatory effect of adiponectin on glucose uptake [73]. 
Compound C has been used widely as an inhibitor of AMPK, yet it inhibits several other 
protein kinases with similar or greater potency in vitro [74-76]. Similarly AraA, which is 
metabolised into ara-ATP, a competitive inhibitor for AMPK [77] has also been reported to 
inhibit adenylyl cyclase, reduce cAMP production and stimulate the mitogenic ERK protein 
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kinases [78] Caution should therefore be exercised in interpreting studies that have used 
compound C and AraA to implicate a role for AMPK.    
 In adipocytes, impaired glucose uptake is reflected by a reduction of glycerol 3-
phosphate production [79], such that inhibition of glucose transport by AMPK is supported 
by the observation that AICAR impaired the incorporation of glucose into lipids in isolated 
rat adipocytes [71,80]. 
 
AS160 
 Insulin-stimulated trafficking of GLUT4 is regulated by two members of the Rab 
GTPase-activating protein (Rab-GAP) family, TBC1D1 and AS160 (also known as 
TBC1D4) (Figure 2) [81]. In muscle, PKB phosphorylates AS160, promoting its interaction 
with 14-3-3 proteins, resulting in inactivation of the Rab-GAP activity and stimulation of 
GLUT4 trafficking. Similarly, AMPK is reported to phosphorylate TBC1D1, thereby 
stimulating GLUT4 trafficking in muscle. In adipocytes TBC1D1 does not appear to play a 
role in GLUT4 trafficking since its expression is very low in 3T3-L1 adipocytes and 
undetectable in WAT from mice [82]. As AS160 plays an essential role in GLUT4 
trafficking in adipocytes [83], it could be reasoned that the differential effects of AMPK 
activation on insulin-stimulated glucose uptake in adipocytes compared to muscle reflect 
the expression of TBC1D1 and AS160 in muscle, but AS160 alone in adipocytes (Figure 
2). Indeed, in primary rat adipocytes, inhibition of insulin-stimulated glucose uptake by 
AICAR was accompanied by a reduction in phosphorylation of AS160 at the PKB site 
Thr651 (equivalent to Thr642 in human), the interaction of AS160 with 14-3-3 and less 
translocation of GLUT4 to the plasma membrane (Figure 2)[72]. Moreover, this study 
shows that infection of rat adipocytes with adenoviruses expressing a kinase-dead mutant 
AMPK1 completely prevented the effect of AICAR on inhibition of insulin-stimulated 
AS160 Thr651 phosphorylation and glucose uptake despite only partial inhibition of 
AICAR-induced AMPK activation [72].  
 AS160 contains multiple phosphorylation sites and PKB phosphorylates Ser318, 
Ser588 and Thr642, and to a lesser extent Ser570 and Ser751 of human AS160 in vitro. 
AMPK on the other hand phosphorylates Ser588 and Ser570 to a similar degree as PKB, 
yet Thr642 is a poor substrate of AMPK compared to PKB, also reflected in less 14-3-3 
binding to AS160 compared to PKB [84]. In 3T3-L1 adipocytes, insulin stimulated 
phosphorylation of AS160 at Ser318, Ser341, Ser570, Ser588, Thr642, Ser666 and 
Ser751. However treatment with AMPK activators AICAR, A769662 and phenformin did 
not phosphorylate AS160 at any of these sites and did not promote 14-3-3 binding [85,86]. 
This suggests that AMPK does not phosphorylate AS160 at the insulin-regulated sites in 
adipocytes, yet no studies to date have examined the effect of AMPK activation on site-
specific AS160 phosphorylation other than Thr642 in the presence of insulin.  
 The mechanism behind this potential inhibition of AS160 phosphorylation by AMPK 
is therefore uncertain. AS160 Thr642 (Thr651) is phosphorylated by p90 ribosomal S6 
kinase (p90RSK) and serum- and glucocorticoid-induced protein kinase (SGK1) in addition 
to PKB in vitro [84].  Although PKB is widely thought to be the kinase responsible for 
phosphorylation at Thr642 in response to insulin, PKB-stimulated phosphorylation of 
glycogen synthase kinase-3 were not affected under conditions in which AMPK activation 
inhibited insulin-stimulated Thr642 phosphorylation [72]. It might be possible that AMPK 
prevents the specific interaction of PKB with AS160, thereby lowering AS160 
phosphorylation. Alternatively, AMPK may activate a phosphatase that dephosphorylates 
AS160 specifically at Thr651.  A third alternative is that AMPK directly phosphorylates 
AS160 and makes it a poorer substrate for PKB phosphorylation, although this seems 
unlikely given the lack of effect on many phosphorylation sites as described above. Finally, 
AMPK might reduce SGK1 or p90RSK-stimulated Thr642 phosphorylation, as both 
kinases have been reported to be sensitive to insulin [86,87].  
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Long term AMPK activation and glucose transport 
 Less is known about the long term effects of AMPK activation in adipose tissue. 
3T3-L1 adipocytes treated with metformin for 24-48 hours inhibited the fold-stimulation of 
glucose transport by insulin due to higher basal uptake [61]. Similarly, human SCAT and 
VAT preadipocyte-derived adipocytes incubated for 24 hours with metformin showed an 
increase in glucose uptake [88]. Furthermore, human SCAT preadipocyte derived 
adipocytes exhibited enhanced insulin stimulated glucose uptake after metformin 
treatment [88]. It has been reported that AMPK activation stimulates GLUT4 expression in 
muscle [89-92] and 5-day metformin treatment in rainbow trout increased WAT GLUT4 
mRNA levels [93], as did prolonged incubation of human SCAT with AICAR ex vivo [94]. In 
contrast, GLUT4 protein levels were unaffected by prolonged AICAR or metformin 
treatment of 3T3-L1 adipocytes or in adipose biopsies from volunteers with type 2 diabetes 
treated with metformin for 10 weeks compared to sulphonylurea treatment [61]. In 
conclusion the majority of evidence supports inhibition of insulin-stimulated glucose 
metabolism by AMPK activation in adipocytes but more studies are necessary to fully 
understand the molecular mechanisms underlying the effect of AMPK.  
 
ROLE OF AMPK IN LIPOLYSIS 
Regulation of lipolysis 
 Lipid droplets in adipocytes are tightly-regulated specialised organelles [95]. In 
lipolysis, TAG is hydrolysed to glycerol and FAs by the successive action of adipose 
triglyceride lipase (ATGL; also known as desnutrin) which converts TAG to diacylglycerol 
(DAG), HSL, which converts DAG into monoacylglycerol (MAG) and MAG lipase, which 
converts MAG to FAs and glycerol (Figure 3). In the fasted state, noradrenergic stimulation 
activates PKA which phosphorylates and recruits the lipid droplet scaffolding protein 
perilipin and HSL to the lipid droplet to stimulate lipolysis [95]. As mentioned previously, 
insulin, via PKB-mediated phosphorylation and activation of PDE3B, stimulates breakdown 
of cAMP, thereby suppressing lipolysis. 
 HSL is phosphorylated by PKA at Ser563 which increases its intrinsic activity and 
Ser659 and Ser660 which are involved in the translocation of HSL from the cytosol to the 
lipid droplet (Figure 3) [96]. In the absence of cAMP, perilipin is associated with the protein 
comparative gene identification-58 (CGI-58). Upon perilipin phosphorylation by PKA, CGI-
58 is released and interacts with ATGL, stimulating lipase activity [97]. In vitro, PKA has 
recently been reported to phosphorylate ATGL at various sites including Ser404 (Figure 3) 
[98], in contrast to an earlier study [99]. Both fasting and exercise increased ATGL 
phosphorylation at Ser406 (equivalent to human Ser404) in mouse epididymal adipose 
tissue [98]. Furthermore, expression of an ATGL Ser406Ala mutant in both HEK293 [100] 
and COS1 cells [98] has been reported to reduce lipolysis, whereas in 293FT cells TAG 
breakdown was not affected [101]. Reduced forskolin-stimulated lipolysis has also been 
reported in adipocytes derived from embryonic fibroblasts of ATGL-/- mice infected with 
retroviruses expressing Ser406Ala mutant ATGL compared to those infected with wild-type 
ATGL, suggesting that Ser404 phosphorylation is important for increased ATGL activity in 
adipocytes [98].  
 
AMPK and lipolysis 
 Several studies report an anti-lipolytic effect of AMPK [40,102,103], whereas others 
suggest AMPK stimulates lipolysis [104,105]. Furthermore, exercise has been reported to 
activate AMPK in rat adipose tissue in a β-adrenergic receptor-mediated fashion and β-
adrenergic-stimulated lipolysis was sensitive to compound C-sensitive manner, suggesting 
that AMPK is necessary for adrenaline-induced lipolysis [105]. It is important, however, to 
note that the FA liberated during lipolysis can directly be re-esterified, thereby consuming 
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ATP. As re-esterification of FA is positively correlated with the rate of lipolysis [106-108], 
an increase in lipolysis may indirectly activate AMPK as a result of an increase in 
AMP:ATP ratio [109]. This increase in AMPK activity could subsequently inhibit lipolysis, 
supported by the observation that mice lacking AMPKα1 have smaller adipocytes with 
higher basal and β-adrenergic-stimulated lipolysis rates [40]. Importantly, activation of 
AMPK by AICAR has been reported to initially inhibit lipolysis both in isolated rat 
adipocytes as well as rats in vivo as reflected by a decrease in serum FAs, yet prolonged 
AICAR treatment increased lipolysis, which the authors attributed to an increase in ATGL 
content as well as activity, since HSL activity was lowered [80]. On the other hand, 
A769662 and salicylate have been reported to reduce fasting plasma FA concentrations in 
an AMPK1-dependent manner, which may be a result of reduced adipose lipolysis, 
supporting a role for AMPK in inhibiting lipolysis in vivo. [28]. 
 In adipocytes isolated from human subcutaneous adipose tissue both biguanides 
and thiazolidinediones inhibited lipolysis in a compound C-sensitive manner, accompanied 
by activation of AMPK [110]. Furthermore, metformin lowered lipolysis in human 
subcutaneous adipose tissue from obese subjects in vivo [111]. However, in isolated rat 
adipocytes metformin has been reported to decrease cellular cAMP levels as well as the 
activity of PKA suggesting the effect of metformin on lipolysis may be mediated by 
inhibition of PKA rather than AMPK activation [112]. 
 
AMPK regulation of ATGL and HSL? 
 Conflicting data have been published concerning the role of AMPK in the regulation 
of HSL. AMPK has been reported to phosphorylate HSL on Ser565, preventing PKA-
stimulated activation of HSL (Figure 3) [102,103,113]. Furthermore, ex vivo AMPK 
activation in human SCAT-derived adipocytes, was demonstrated to reduce HSL 
translocation to the lipid droplet in association with a compound C-sensitive inhibition of 
lipolysis [110]. In contrast, mutation of Ser565 to Ala has been reported to prevent the 
translocation of HSL to the lipid droplet in 3T3-L1 adipocytes, suggesting Ser565 
phosphorylation does not inhibit lipolysis and expression of a dominant negative mutant 
AMPK had no effect on HSL Ser565 phosphorylation under basal or β-adrenergic-
stimulated conditions, calling into question AMPK regulation of this site [114,115].  
 Intriguingly, ATGL Ser404 is an AMPK consensus site and ATGL Ser404 can be 
phosphorylated by AMPK in vitro [98,100]. In support of this, HEK293 cells and 3T3-
L1ΔCAR adipocytes stimulated with AICAR have been reported to exhibit increased ATGL 
phosphorylation at Ser406, which was suppressed by compound C [100]. Furthermore, 
expression of Ser406Ala mutant ATGL completely prevented AICAR-induced lipolysis, 
whilst injection of mice with AICAR increased serum FA levels, which was not seen in 
adipose-specific ATGL knockout mice, supporting an ATGL-mediated pro-lipolytic action of 
AMPK [100]. More recently it was reported that ex vivo AICAR stimulation did not stimulate 
ATGL Ser404 phosphorylation or lipolysis in subcutaneous adipose tissue from obese 
subjects [98]. 
 Taken together, these data suggest AMPK may phosphorylate ATGL and HSL to 
regulate lipolysis (Figure 3), but conclusions are difficult to draw given the lack of studies 
using tools to manipulate AMPK specifically. Furthermore, the overall effect of AMPK 
activation on lipolysis is still controversial and the duration and mode of AMPK activation 
may be of particular importance.  
 
AMPK REGULATION OF LIPOGENESIS 
 Early studies in isolated rat adipocytes reported AICAR inhibited lipogenesis and 
stimulated phosphorylation of ACC, the key regulated step of fatty acid synthesis and fatty 
acid oxidation (Figure 3) [102]. ACC catalyses the synthesis of malonyl-CoA from acetyl-
CoA and is inhibited by AMPK-mediated phosphorylation at Ser79 on ACC1 or the 
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orthologous site Ser212 on ACC2. ACC1 is mainly expressed in lipogenic tissues such as 
WAT and isolated rat adipocytes infected with adenoviruses expressing constitutively 
active mutant AMPK showed increased phosphorylation of ACC1 Ser79 whereas infection 
with dominant negative mutant AMPK inhibited AICAR-stimulated phosphorylation of 
Ser79, indicating that ACC is certainly regulated by AMPK in adipocytes [40]. This is 
further supported by the observation that both fasting and exercise stimulate AMPK in rat 
adipose tissue with a concomitant reduction in malonyl-CoA, which may reflect inhibition of 
ACC and increased malonyl-CoA decarboxylase activity [40,50,116,117].   
 Prolonged activation of AMPK by leptin or AICAR in rat adipose tissue [80,118] and 
metformin in human adipose tissue [61] increased ACC phosphorylation and lowered the 
expression of lipogenic genes including ACC. In addition, adipocytes from AMPK1-/- mice 
showed increased lipogenesis in adipose explants [43], suggesting a specific role for 
complexes containing this subunit isoform in attenuating lipogenesis. Lipogenic gene 
expression is under the control of the sterol regulatory element binding protein 1c 
(SREBP-1c) transcription factor. In liver AMPK has been reported to phosphorylate and 
inactivate SREBP-1c, thereby decreasing the expression of lipogenic genes including 
ACC1, fatty acid synthase (FAS), and stearoyl-CoA desaturase 1 (SCD1) [119]. There is, 
however, a dearth of studies examining AMPK regulation of SREBP-1c in adipose tissue. 
In 3T3-L1 preadipocytes, AICAR inhibited expression of SREBP-1c, yet AICAR treatment 
for 6 weeks was without effect on SREBP-1c expression in epididymal WAT [120]. Taken 
together, these data indicate that AMPK activation in adipose tissue is linked to decreased 
lipid storage by lowering TAG synthesis (Figure 3), but the role of SREBP-1c-regulated 
lipogenic gene expression in the action of AMPK in adipose tissue is yet to be fully 
addressed. It is clear that more specific strategies to down- or up-regulate AMPK in 
adipocytes are required to assess the role of AMPK in both lipogenesis and lipolysis.  
 
AMPK REGULATION OF FATTY ACID OXIDATION 
 Malonyl-CoA is not only a precursor for FA synthesis but also regulates FA 
oxidation by inhibiting carnitine palmitoyltransferase I (CPT1), the rate-limiting enzyme of 
FA entry into the mitochondrion for subsequent oxidation. As AMPK-mediated 
phosphorylation and inactivation of ACC reduces malonyl-CoA concentrations, inhibition of 
CPT1 is relieved and AMPK stimulates FA oxidation in many tissues [1-3]. Despite this, 
acute stimulation of isolated rat adipocytes with AICAR has been reported to inhibit FA 
oxidation, suggested to be due to reduced FA uptake [71]. AMPK activation has recently 
been reported to stimulate translocation of the FA transporter CD36 to the plasma 
membrane in an AS160-mediated manner in cardiomyocytes [121]. Since CD36 and 
GLUT4 both undergo similar trafficking routes [122], it is tempting to speculate AMPK 
activation inhibits CD36 translocation to the plasma membrane in an analogous fashion to 
GLUT4 in adipocytes, thereby providing a mechanism for reduced FA uptake through 
AMPK activation (Figure 3). To our knowledge there have been no studies on the effect of 
AMPK on FA transporters including CD36 in adipocytes. 
 In contrast to the rapid inhibition of FA oxidation by AICAR [71], sustained activation 
of AMPK stimulated FA oxidation [80,123] and increased mitochondrial content in 
adipocytes [118,124]. In support of this, sustained AICAR stimulation increased WAT 
expression of peroxisome proliferator-activated receptor (PPAR), PPAR and PPAR 
coactivator-1 (PGC-1), all of which influence the expression of enzymes involved in FA 
oxidation and mitochondrial biogenesis [80,100]. These structural changes in adipocytes 
after prolonged AICAR administration were accompanied by a reduction in body fat mass. 
However it is important to note that whole body energy expenditure was increased after 
sustained treatment with AICAR as AMPK activation also increases the oxidative capacity 
of liver and muscle [125,126]. As with lipolysis, the role of AMPK in the regulation of WAT 
FA oxidation may therefore be dependent on the duration and mode of AMPK stimulation, 
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whereby AMPK activation rapidly inhibits FA oxidation, potentially due to effects on FA 
transport, yet prolonged AMPK activation stimulates FA oxidation.  
 
AMPK AND ADIPOGENESIS 
 Differentiation of preadipocytes involves a highly regulated transcriptional cascade 
induced by hormones including insulin and glucocorticoids and is characterised by 
expression of FAS and adipocyte-specific fatty acid binding protein (aP2) in addition to 
increased expression of the PPAR and CCAAT/enhancer binding protein (C/EBP) 
transcription factors [127]. The process begins with re-entry of growth-arrested 
preadipocytes into the cell cycle where they undergo several rounds of mitosis. This initial 
phase is known as mitotic clonal expansion (MCE) and is accompanied by the transient 
expression of C/EBP and C/EBP. These transcription factors subsequently stimulate 
transcription of PPAR, which in turn can activate C/EBP. PPAR and C/EBP exist in a 
positive feedback loop to propagate differentiation and induction of late adipogenic genes 
including aP2 and Fas in the terminal differentiation phase [128]. 
 Proliferation and adipogenesis are anabolic processes which multiple lines of 
evidence suggest are inhibited by AMPK. Activation of AMPK has been proposed to 
suppress proliferation in a variety of cell types in different ways. Most recently, studies in 
cell lines using AICAR or metformin have proposed AMPK inhibits proliferation via 
inhibition of mTOR [1,129]. Stimulation with AICAR, A769662 and infection with viruses 
expressing a constitutively active mutant AMPK have been reported to inhibit endothelial 
cell proliferation via elevation of p21 and p27 expression [130] and AICAR has been 
demonstrated to block growth of the HepG2 cell line via phosphorylation of p53, all leading 
to cell cycle arrest [131]. The exact mechanism by which AMPK inhibits proliferation 
remains to be fully elucidated, particularly in preadipocytes of WAT, and may differ 
depending on the type of cell. 
 AMPK activation has been suggested to inhibit adipogenesis via the MCE phase, 
with reduced expression of C/EBP (which is essential for initiation of the adipogenic 
transcriptional cascade), and subsequent inhibition of PPAR, C/EBP and late adipogenic 
markers such as FAS, aP2 and SREBP-1c [132]. It has been demonstrated in 3T3-L1 
preadipocytes that A769662 inhibited accumulation of lipid droplets and reduced 
expression of C/EBP and PPAR as well as earlier adipogenic transcription factors 
C/EBP and C/EBP [42]. Interestingly, A769662 was shown to maintain C/EBP 
expression, where it would normally decline [42]. AICAR treatment blocked adipogenesis 
at the MCE phase and reduced expression of C/EBP, PPAR SREBP-1c and aP2 
[120,132]. Recently, novel synthetic compounds which are structurally similar to 
resveratrol have been identified which have been proposed to activate AMPK indirectly 
[133]. As with other established AMPK activators, they have been found to inhibit 
differentiation during the MCE phase and reduce expression of several adipogenic 
markers, including PPAR, C/EBP, FAS and aP2 [133]. 
While these studies all indicate AMPK acts at the early proliferation phase to inhibit 
adipogenesis, the exact mechanism by which AMPK produces these effects is still unclear. 
It has recently been suggested that AICAR may inhibit adipocyte differentiation via 
modulation of the WNT/β-catenin pathway [134].  In that study, AICAR stimulation during 
adipogenesis of 3T3-L1 adipocytes led to an increase in β-catenin expression and nuclear 
accumulation concomitant with the significant reduction in expression of adipogenic genes; 
this was ablated with siRNA-mediated knockdown of β-catenin, providing a possible 
mechanism by which AMPK inhibits adipogenesis [134].  Furthermore, AMPK activation 
has been proposed to maintain expression of preadipocyte factor-1 (Pref-1) which inhibits 
adipogenesis [135]. 
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An increase in adipose tissue mass can either be due to an increase in adipocyte 
size (hypertrophy), an increase in adipocyte number (hyperplasia), or both. Studies using 
mice in which catalytic subunit isoforms of AMPK have been knocked out have been used 
to examine the role of AMPK in changes in adipose tissue mass. AMPK2 deficient mice 
fed a high fat diet exhibited increased adipose tissue mass compared to wild type 
littermates, resulting from adipocyte hypertrophy, with no change in cell number or 
adipogenic marker expression [136]. Similar observations were made in a recent study 
which demonstrated AMPK1-deficient mice fed a high fat diet also showed increased 
adiposity compared with their wild type littermates, and that this was the result of adipocyte 
hypertrophy [137].  Caution has to be taken when interpreting these data as this may 
reflect ablation of AMPK-mediated increased fatty acid oxidation and a concomitant 
decrease in lipogenesis. Also the animal models utilised in these studies have a global 
knockout of either AMPK isoform, such that observed effects may not be a direct effect of 
reduced AMPK activity in adipose or adipocytes. There is a need for adipose-specific 
knockouts of AMPK isoforms to help address this. 
 
REGULATION OF ADIPOSE ADIPOCYTOKINES AND INFLAMMATION BY AMPK  
As mentioned previously, WAT has an endocrine function in addition to its key role 
in metabolism, secreting a large number of adipocytokines, which influence systemic and 
local metabolism in addition to inflammatory pathways. Dysfunctional metabolism and a 
chronic sub-clinical proinflammatory environment are observed in the WAT of obese 
individuals, and this proinflammatory environment contributes to the development of 
systemic insulin resistance and type 2 diabetes [5].  
 
Adipocytokines 
Proteins secreted by WAT that influence metabolism and inflammation include 
leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor- 
(TNF-), interleukin (IL)-1β and IL-6. Plasma leptin levels are positively correlated with an 
increase in total body fat mass as a result of more leptin being released from large, 
hypertrophic adipocytes compared with smaller adipocytes [138].  Leptin acts at neurones 
within the hypothalamus to regulate satiety, but also exerts antidiabetic actions 
independent of its effect on body mass [139]. Adiponectin is a protein secreted exclusively 
from adipose tissue [140], with plasma levels correlating negatively with obesity [141]. 
Adiponectin acts to improve peripheral insulin sensitivity and has systemic anti-
inflammatory effects [142]. MCP-1, TNF-α, IL-1β and IL-6 are proinflammatory chemokines 
or cytokines secreted by WAT, and are increased in concentration upon obesity [143].  
 
Proinflammatory adipocytokines and obesity 
Obesity is associated with the low-grade inflammation of WAT and increased 
necrosis/apoptosis of adipocytes [144]. Proinflammatory cytokines signal via distinct 
pathways, with TNF-α and IL-1 signalling via the proinflammatory transcription factor 
nuclear factor B (NFB) and MAP kinases, whereas IL-6 signals via a JAK/STAT 
pathway [4]. These pathways culminate in the secretion of chemokines including MCP-1, 
recruiting macrophages to the site of inflammation [145,146]. Studies in genetically obese 
(ob/ob) and high fat diet-induced obese mice have suggested the presence of other 
chemokine receptors and ligands, including macrophage inflammatory protein-1 (MIP-1), 
RANTES (regulated and normal T cell expressed and secreted) and MCP-2 are also 
upregulated in obesity [147], demonstrating the complexity of the proinflammatory profile 
of obese adipose tissue. Migration of macrophages into adipose tissue is also stimulated 
by necrotic adipocytes [144], nutrient excess (increased FA) (Figure 4) [148], or a 
combination of these. Interplay between the different cell types within adipose tissue, 
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particularly between adipocytes and macrophages, is central to the development of 
inflammation within the tissue. Several genetic studies have demonstrated the importance 
of macrophages in the development of obesity-related inflammation and insulin resistance 
[149-152]. Macrophages have been reported to aggregate and form crown-like structures 
surrounding necrotic adipocytes (Figure 4) [143,153,154]. Macrophages can also be 
recruited and rendered proinflammatory by the presence of saturated FAs (as is often the 
case in obesity) which activate the Toll-like receptor (TLR) family [155]. Indeed, mice with 
hematopoietic deletion of TLR are largely protected from obesity-induced inflammation and 
insulin resistance [156]. Following migration into adipose tissue in response to one or more 
of the factors detailed above, macrophages then undergo a shift in their polarity, switching 
from an anti-inflammatory, ‘alternatively activated’ M2 state to a ‘classically activated’, 
proinflammatory M1 state (Figure 4) [5]. Conversely, adiponectin has been reported to 
switch adipose macrophages into the anti-inflammatory M2 state [142]. Macrophages can 
also induce inflammatory responses via activation of the inflammasome, the best -
characterised of which is the nucleotide-binding and oligomerisation domain-like receptor 
family pyrin domain-containing 3 (NLRP3) inflammasome. Activation of the NLRP3 
inflammasome leads to maturation and secretion of proinflammatory cytokines IL-1 and 
IL-18, and as a result has been linked to obesity-associated inflammation and 
development of insulin resistance and type 2 diabetes [157]. 
 
 
AMPK inhibits inflammation in adipose tissue 
There have been a number of studies suggesting AMPK is anti-inflammatory in 
different tissues and cell types including those that constitute adipose such as adipocytes, 
endothelial cells and macrophages [4]. Various studies have reported that activation of 
AMPK can inhibit synthesis of proinflammatory cytokines such as TNF-, IL-1 and IL-6 in 
macrophages [45,47,158,159] and IL-6 and IL-8 in adipocytes [94]. Conversely, AMPK 
activation has been reported to upregulate expression of anti-inflammatory cytokine IL-10 
in macrophages [47,159]. In human SCAT cultured ex vivo, AICAR was reported to reduce 
TNF- and IL-6 secretion (Figure 4) [37]. Berberine, which activates AMPK and inhibits 
proinflammatory signalling in isolated macrophages also been reported to inhibit cytokine 
expression in adipose tissue of obese db/db mice, yet the AMPK-dependence of this has 
not been demonstrated [158]. A very recent study has shown that activation of the NLRP3 
inflammasome is markedly increased in myeloid cells from patients with type 2 diabetes, 
and found that treatment with metformin appeared to reduce maturation and secretion of 
IL-1 and IL-18 in monocyte-derived macrophages. This was suggested to occur in an 
AMPK-dependent manner; however the mechanism remains to be elucidated [160]. 
Recent studies have utilised AMPK-deficient mice to confirm the anti-inflammatory 
role of AMPK. It has been reported that high fat diet-fed AMPK1-/- mice had an increased 
level of infiltration of proinflammatory macrophages and exhibited an elevation in IL-6, IL-
1 and TNF- at the mRNA level in adipose tissue, as well as significantly higher levels of 
circulating cytokines [137].  Furthermore, increased production of IL-1 and TNF- (but not 
IL-6) were observed in AMPK1-deficient macrophages stimulated with TLR4 activator 
lipopolysaccharide, and these macrophages displayed increased activity of 
proinflammatory signalling pathways compared with wild type macrophages [137]. Stable 
knockdown of AMPK1 in 3T3-L1 adipocytes supported these findings, with higher mRNA 
levels of proinflammatory cytokines TNF- and IL-1 as well as MCP-1 in response to FA 
treatment than control 3T3-L1 cells [137]. Similarly, a study utilising obese AMPK1-/- mice 
reported that AMPK activation is crucial for the regulation of macrophage polarisation, as 
bone marrow-derived macrophages from mice lacking the 1 subunit had reduced levels 
of AMPK activation and elevated c-Jun N-terminal kinase (JNK) phosphorylation in 
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response to proinflammatory stimuli [47]. Interestingly, however, the ability of AMPK to 
suppress palmitate-stimulated JNK phosphorylation appears to be blocked by inhibition of 
fatty acid oxidation [47]. 
It has been shown that activation of AMPK drives anti-inflammatory polarisation 
macrophages to M2, (Figure 4) while inhibition of AMPKα expression by RNA interference 
or transfection with a dominant negative form of AMPK significantly enhanced mRNA and 
protein expression of TNF-α and IL-6 [159]. Furthermore, PPARγ-coactivator-1β (PGC1β) 
and oxidative metabolism has been reported to be important in priming macrophages for 
alternative activation and attenuates proinflammatory signalling, suggesting resident M2 
macrophages are reliant upon FA metabolism and AMPK activity to maintain the anti-
inflammatory phenotype [159,161]. Conversely, macrophages from AMPK1-/- mice were 
found to have reduced mitochondrial content consistent with their M1 activation and 
reduced rates of fatty acid oxidation [47]. There is evidence to suggest that mature 
adipocytes may modulate macrophage polarisation via secretion of lipid mediators which 
activate AMPK in macrophages and impair their polarisation to a pro-inflammatory 
phenotype [162]. 
 
Adipocytokines Regulated by AMPK 
As previously described, AMPK activation has been reported to suppress 
inflammatory responses in obese adipose tissue [37,94,158,163]. Adiponectin and leptin 
levels may also be regulated by AMPK as high fat diet-fed AMPK1-/- mice displayed 
significantly less adiponectin and increased leptin concentrations relative to chow-fed or 
wild type littermates [47]. Also, AICAR increased adiponectin gene expression in human 
SCAT cultured ex vivo [37]. These data suggest that AMPK activation is partially able to 
override obesity-induced dysregulation of adiponectin and leptin concentrations. However, 
AICAR and metformin have also been reported to suppress adiponectin expression in 3T3-
L1 adipocytes [164]. 
 
AMPK regulation by adipocytokines 
Adipocytes express adiponectin receptors, indicating that adiponectin can act in an 
autocrine fashion [165].  Adiponectin stimulates AMPK activity in several tissues by a 
mechanism that has yet to be fully characterised, but adiponectin also engages many 
other signalling pathways and has AMPK-independent effects [142]. A few studies have 
suggested that AMPK itself can be regulated by proinflammatory cytokines in different cell 
types, for example TNF- has been reported to activate AMPK in various cell lines 
including endothelial and kidney cell lines [166]. Conversely, it has been reported to 
suppress AMPK activity in myotubes and muscle [167]. IL-6 has similarly been reported to 
influence AMPK activity in different cell types are also varied, with evidence suggesting IL-
6 stimulates AMPK in muscle, with suppressed AMPK activity being reported in IL-6-
deficient mice  [168,169], yet in endothelial cells IL-6 has been proposed to inhibit AMPK 
activity [170]. In a recent study IL-6 was found to increase phosphorylation of ACC and 
AMPK in cultured epididymal adipose tissue (eWAT) and was independent of any increase 
in lipolysis [171]. It is therefore apparent that certain adipocytokines may regulate AMPK 
activity, however this is appears to be cell type-specific and further investigation is 
required, particularly to elucidate the effect of adipocytokines on AMPK in adipose tissue. 
 
AMPK AND BROWN ADIPOSE 
As mentioned previously, brown adipocytes contain high numbers of mitochondria 
and characteristically express UCP1, which allows thermogenesis, yet the exact role of 
BAT in human energy balance remains uncertain [6,7]. Cold exposure has been reported 
to stimulate AMPK in BAT from rats and mice [38,52] and both AICAR and 3-adrenergic 
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stimulation increase AMPK activity and glucose transport in cultured mouse brown 
adipocytes in an AraA-sensitive manner [172,173].  These findings have been extended in 
mice, indicating that adrenergic nerves stimulate AMPK in BAT in vivo [174].  Furthermore, 
AMPK activity increases during brown adipocyte differentiation, and siRNA targeted to 
AMPK inhibited differentiation into mature brown adipocytes, suggesting AMPK promotes 
differentiation into thermogenic BAT [175]. Indeed, prolonged treatment of mice with 
AICAR increased the extent of BAT within WAT deposits in mice [175].  These studies 
suggest that AMPK may play a role in differentiation into FA oxidising BAT, leading to 
greater energy expenditure, yet AMPK1-/- mice showed no alteration in cold tolerance or 
acute nonshivering thermogenesis, although a compensatory increase in AMPK2 
expression may explain this lack of effect [176]. 
 
REGULATION OF AMPK IN HUMAN ADIPOSE 
 In adipocytes isolated from the SCAT of normal to moderately overweight women, 
the thiazolidinedione and biguanide antidiabetic drugs have been demonstrated to activate 
AMPK and inhibit lipolysis in a compound C-sensitive manner ex vivo [110]. Similarly, 
cultured SCAT explants from similar individuals stimulated with AICAR exhibited increased 
adiponectin and GLUT4 expression and reduced TNF-, IL-8 and IL-6 secretion [37,94]. 
Few studies have examined human adipose AMPK activity in vivo, however. Of these, 
exercise has been reported to activate AMPK in SCAT from healthy individuals [49], yet 
this may depend on the degree of exercise, as a further study has indicated that SCAT 
AMPK activity is unaffected [177].  AMPK expression and activity has been reported to be 
lower in VAT compared to SCAT of morbidly obese individuals [178,179]. Furthermore, 
when this morbidly obese group was divided into insulin resistant and insulin sensitive 
subgroups, AMPK activity was reduced in the adipose tissue of the insulin resistant obese 
volunteers compared to BMI-matched controls, suggesting an association in WAT between 
AMPK activity and insulin sensitivity [179,180]. Intriguingly, AMPK activity is also reported 
to be decreased in VAT from individuals with Cushing’s syndrome, which is also 
associated with insulin resistance [181]. Finally, metformin was recently shown to increase 
SCAT AMPK activity of individuals with type 2 diabetes in a randomised glycaemia-
controlled crossover study [61]. Although these clinical studies have been on small 
numbers of people, these data do suggest that improving AMPK activity in adipose tissue 
in people with insulin resistance may benefit adipose function and that exercise and 
metformin may be able to achieve this. It has yet to be proven whether the activation of 
AMPK observed with exercise, metformin or in more insulin-sensitive individuals 
represents increased AMPK activity in adipocytes or the other constituent cells of adipose, 
however. 
 
CONCLUSIONS 
The studies of AMPK function in adipose published to date are largely based on 
isolated rodent adipocytes or cells that have been differentiated into adipocytes in vitro. As 
these cells are intractable to molecular biology techniques that would allow specific up- or 
downregulation of AMPK, most studies have relied on less specific methods of transiently 
activating or inhibiting AMPK. Similarly, data obtained in animals where one isoform of 
AMPK has been genetically deleted have revealed interesting potential actions of AMPK in 
adipose tissue, but these may represent secondary indirect effects mediated by 
downregulation of AMPK in other tissues, particularly liver and muscle. There is, therefore, 
an urgent need for animals in which AMPK is specifically ablated in adipocytes to confirm 
the actions of AMPK in adipose. The heterogeneity of adipose tissue in terms of 
constituent cell types and different depots increase the challenge of determining the 
function of AMPK in adipose tissue.  The exciting new observations concerning the role of 
BAT in man is another area in which the role of AMPK should be explored. The few 
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investigations of AMPK activity in human adipose have demonstrated that AMPK 
activation in adipose tissue is feasible in man and that this may have beneficial 
consequences attenuating adipose dysfunction and inflammation.  As activators, such as 
A769662 and salicylate, that target specific subunit isoforms of AMPK are already used in 
the laboratory, it is feasible to design activators of AMPK are targeted to certain tissues, 
given the differential tissue distribution of AMPK subunit isoforms. It is clear, therefore, that 
AMPK regulates carbohydrate and lipid metabolism in adipose tissue and suppresses 
proinflammatory signalling that contributes to adipose tissue dysfunction and insulin 
resistance. More studies that specifically manipulate AMPK activity in the constituent cells 
of adipose tissue are required to further characterise its role. 
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FIGURE LEGENDS 
 
 
 
 
Figure 1  Regulation of AMPK. 
AMPK is activated by phosphorylation of the  catalytic subunit at Thr172 by LKB1 or 
CaMKK. Increased AMP or ADP concentrations (relative to ATP) bind to the regulatory  
subunit, allosterically activating AMPK and inhibiting dephosphorylation of Thr172 by an as 
yet uncharacterised protein phosphatase (P-ase). Neither LKB1 nor CaMKK are 
regulated directly by adenine nucleotides. Increased intracellular Ca2+ stimulates 
CaMKK-mediated AMPK activation independent of changes in adenine nucleotide ratios.  
The antidiabetic drugs metformin and rosiglitazone (thiazolidinedione) increase AMP:ATP 
or ADP:ATP concentrations, thereby activating AMPK. The plant-derived compounds 
resveratrol, galgeine and berberine also activate AMPK by this mechanism. AICAR is 
phosphorylated to the nucleotide ZMP, which mimics AMP, thereby activating AMPK 
without altering adenine nucleotide ratios. A769662 and salicylate are reported to activate 
AMPK complexes containing the 1 regulatory subunit directly. 
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Figure 2  Regulation of insulin stimulated GLUT4 translocation in adipocytes by 
AMPK. 
Insulin binding to the insulin receptor results in activation of PKB which in turn 
phosphorylates AS160 at Thr642. This enhances 14-3-3 binding to AS160 and inhibits 
AS160 Rab-GAP activity permitting GLUT4 to translocate from GLUT4 storage vesicles 
(GSV) to the plasma membrane (PM). The substantial increase in GLUT4 at the plasma 
membrane increases glucose transport. Activated AMPK has been reported to reduce 
insulin-stimulated Thr642 phosphorylation and 14-3-3 binding to AS160 although the 
mechanism by which this occurs remains uncertain. 
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Figure 3  Regulation of adipocyte lipid metabolism by AMPK. 
Lipolysis is stimulated by -adrenergic receptor (-AR)-mediated stimulation of cAMP 
production, resulting in PKA activation. PKA phosphorylates HSL and ATGL, increasing 
lipolysis, although whether ATGL phosphorylation by PKA in vivo remains uncertain. 
AMPK activation has been reported to influence lipolysis by (1) phosphorylation of HSL at 
Ser565, thereby preventing PKA-mediated HSL phosphorylation at Ser563 and 
subsequent lipolysis; (2) phosphorylation and activation of ATGL, thereby stimulating 
lipolysis. ATP-consumption during re-esterification of FAs after lipolysis may also activate 
AMPK (3), such that regulation of lipolysis by AMPK is likely to be dependent on the 
duration and mode of AMPK activation. AMPK phosphorylates and inactivates ACC in 
adipocytes, reducing FA synthesis and may inhibit the expression of ACC and FAS genes 
(4).  It has also been suggested that AMPK activity inhibits FA oxidation due to reduced FA 
transport (5), mediated by FA transporters including CD36/FATP, yet this remains to be 
examined in adipocytes. 
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Figure 4 Anti-inflammatory actions of AMPK in adipose tissue. 
In lean adipose tissue, small adipocytes and alternatively activated macrophages secrete 
adipocytokines such as IL-10 and adiponectin, which maintain an anti-inflammatory 
environment. Production of these adipocytokines is promoted by activated AMPK. Excess 
calorie intake leads to the development of a pro-inflammatory environment within obese 
adipose tissue. Adipocytes enlarge, becoming hypertrophic and often necrotic, and there is 
an increased infiltration of macrophages. The proinflammatory environment drives 
macrophage polarisation towards the classically activated M1 state, and they tend to 
accumulate around necrotic adipocytes, forming crown-like structures. The secretory 
products of the macrophages and hypertrophic adipocytes further exacerbate this 
inflammation. Adipose tissue inflammation is linked to obesity-related insulin resistance 
and type 2 diabetes. Activation of AMPK can inhibit production of proinflammatory 
cytokines and chemokines, increase adiponectin secretion and inhibit macrophage 
recruitment and M1 polarisation, thereby potentially reducing insulin resistance. 
 
 
 
